CMS 2026 Final Rule and Program Instructions Codify IRA Part D Provisions in Preparation for First Year of Selected Drugs Under Medicare Drug Price Negotiation Program
This Bulletin is brought to you by AHLA’s Payers, Plans, and Managed Care Practice Group.
- May 29, 2025
- Joshua Galuska , BRG
In April, the Centers for Medicare & Medicaid Services (CMS) released the CY 2026 Medicare Advantage and Part D Final Rule (2026 Final Rule) and Final CY 2026 Program Instructions (2026 Final Program Instructions), each of which updates and codifies provisions from the Inflation Reduction Act of 2022 (IRA). Industry participants should familiarize themselves with these documents to prepare for the first plan year in which Selected Drugs (i.e., drugs subject to a Maximum Fair Price (MFP)) will be available under the Medicare Drug Price Negotiation Program (Negotiation Program), which this article details. Part 2 of this Medicare Advantage and Part D Final Rule Bulletin focuses on other changes included in the 2026 Final Rule as well as which proposals CMS declined to finalize this time around.
ARTICLE TAGS
You must be logged in to access this content.